Bayer Posts 1.2% YOY Sales Decline in 2023 with Pharmaceuticals and Consumer Health Segment Updates
Germany’s Bayer (ETR: BAYN) has released its financial results for 2023, marking a year of...
Finance
Vivolight Medical Secures Over RMB 100 Million in Strategic Financing to Boost Global Expansion
Shenzhen Vivolight Medical Device & Technology Co., Ltd, a Chinese medical device company nurtured and...
Sino-Biocan Secures Series B Funding to Boost Cell and Gene Therapy Production Platforms
Sino-Biocan (Shanghai) Biotech Ltd, a provider of automated, modularized, closed cell production platforms for the...
Angitia Bio Secures USD 40 Million in Series B+ Financing to Advance Musculoskeletal Disorder Therapies
Angitia Biopharmaceuticals, a Guangzhou-based developer of therapies for bone, joint, and muscle diseases, has announced...
Viatris Eyes Growth After Concluding Initial Phase of Strategy with 2023 Sales at $15.4 Billion
US generics giant Viatris (NASDAQ: VTRS) reported a 4% year-on-year decline in global sales to...
Simcere Pharmaceutical’s Oncology Unit Raises RMB 970 Million to Advance Cancer Drug Development
Simcere Pharmaceutical Group (HKG: 2096) has announced that its oncology subsidiary, Simcere Zaiming Pharmaceutical Co.,...
CardioACC Initiates Regulatory Study for Groundbreaking 7.5F Intracardiac Ultrasound System
CardioACC, a Shenzhen-based company specializing in cardiovascular interventional imaging and treatment technologies, has launched a...
Sinopharm Plans to Privatize China Traditional Medicine Holdings in a USD 2 Billion Deal
China Traditional Medicine Holdings (HKG: 0570; China TCM) has announced that its controlling shareholder, the...
Shenzhen Eureka Biotechnology Secures RMB 300 Million in Series B+ Funding for CGT Expansion
Shenzhen Eureka Biotechnology Co., Ltd., a specialist in cell and gene therapy (CGT) based in...
Evopoint Biosciences Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization
Evopoint Biosciences Co., Ltd., a Suzhou-based biopharmaceutical company, has announced the successful completion of a...
AstraZeneca Reports 6% Revenue Growth in 2023, Driven by Oncology and Diabetes Drug Sales
AstraZeneca (AZ; NASDAQ: AZN), the UK-based multinational, reported its financial results for 2023 this week,...
Gilead’s 2023 Flat Sales Reflect Stagnation and COVID-19 Demand Decline
Gilead Sciences Inc. (NASDAQ: GILD) has reported a stagnant performance for the year 2023, with...
Gilead’s 2023 Stagnation Foresees Flat 2024 Sales as Veklury Revenues Dwindle
Gilead Sciences (NASDAQ: GILD) has reported a stagnant performance for 2023, with product sales remaining...
Amgen’s Q4 2023 Results Showcase 9% YOY Growth, 18 Drugs Hit Record Sales
Biopharmaceutical giant Amgen (NASDAQ: AMGN) has reported its financial results for Q4 2023, announcing annual...
Eli Lilly’s 2023 Revenue Soars on Metabolism Drugs, Anticipates Further Growth in 2024
Eli Lilly and Company (NYSE: LLY) reported a robust 2023 financial performance with a 20%...
BMS Sees Mixed Results in 2023: Growth in New Products Offset by Loss of Exclusivity
Bristol Myers Squibb (BMS; NYSE: BMY) reported a 2% year-on-year contraction in 2023 revenues, excluding...
Matridx Bio Secures Series C+ Funding to Advance Infectious Pathogens Diagnostics
Hangzhou Matridx Biotechnology Co., Ltd, a specialist in molecular diagnostics for infectious pathogens based in...
Roche Posts Modest 2023 Growth Amid Shifts in Demand for COVID-Related Products
Swiss pharmaceutical giant Roche (SWX: ROG) has published its 2023 financial results, showing a modest...
Takeda Reports Flat 9-Month Revenue Growth Amid Pipeline Optimization Efforts
Takeda (TYO: 4502), a leading Japanese pharmaceutical company, has released its financial results for the...
Rebecca Tech Secures USD 10 Million in Series A++ Funding to Expand Micro RF Technology Globally
Rebecca Tech LLC, a Hangzhou-based manufacturer specializing in microelectromechanical RF (radiofrequency) technology, has announced the...